Skip to main content

Table 4 Patient safety profile according to time of temozolomide failure, and for the entire population

From: A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

Variable B0 B1 B2 B3 All patients
Number of patients 20 50 45 48 163
Leucopoenia
 G 0 65 (13) 78 (39) 68.9 (31) 62.5 (30) 69.3 (113)
 G 1-2 20 (4) 20 (10) 18.9 (13) 25 (12) 23.9 (39)
 G 3-4 15 (3) 2 (1)* 2.2 (1)* 12.5 (6) 6.7 (11)
Thrombocytopenia
 G 0 65 (13) 52 (26) 62.2 (28) 66.7 (32) 60.7 (99)
 G 1-2 25 (5) 38 (19) 35.6 (16) 16.6 (8) 19.4 (48)
 G 3-4 10 (2) 10 (5) 2.2 (1)* 16.7 (8) 9.8 (16)
Anemia
 G 0 80 (16) 96 (48) 93.3 (42) 97.9 (47) 93.9 (153)
 G 1-2 15 (3) 2 (1) 6.6 (3) 2.1 (1) 5 (8)
 G 3-4 5 (1)* 2 (1)* 0 0 1.2 (2)*
Neutropenia
 G 0 90 (18) 94 (47) 100 (45) 75 (36) 89.6 (146)
 G 1-2 5 (1) 6 (3) 0 12.5 (6) 6.1 (10)
 G 3-4 5 (1) 0 0 12.5 (6) 4.3 (7)
Lymphopenia
 G 0 100 (20) 92 (46) 100 (45) 77.1 (37) 90.8 (148)
 G 1-2 0 6 (3) 0 14.6 (7) 6.1 (10)
 G 3-4 0* 2 (1)* 0* 8.4 (4) 3.1 (5)
Hepatic
 G 0 80 (16) 96 (48) 95.6 (43) 93.8 (45) 93.3 (152)
 G 1-2 20 (4) 2 (1) 4.4 (2) 4.2 (2) 5.5 (9)
 G 3-4 0 2 (1) 0 2.1 (1) 1.2 (2)
  1. *No grade 4 toxicity was detected. B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.